Publications by authors named "Volker Koscielny"
Background: The Patient-Reported Outcomes in Actinic Keratosis (PROAK) study evaluated patient- and clinician-reported outcomes (PRO; ClinRO) during 24 weeks of follow-up among adult patients with actinic keratosis (AK) on the face or scalp who were administered tirbanibulin 1% ointment in real-world community practices in the United States. Methods: Quality of life (QoL) was assessed by Skindex-16 at week (W) 8. Additionally, effectiveness (Investigator Global Assessment [IGA]), PRO and ClinRO (Treatment Satisfaction Questionnaire for Medication and Expert Panel Questionnaire), safety, and tolerability were assessed at W8 and W24.
View Article and Find Full Text PDFArticle Synopsis
- Patient-reported outcomes (PROs) are being recognized as important in assessing the impact of acne vulgaris (AV), particularly with the use of sarecycline in real-world settings, which lacks existing data.
- A study involved 253 patients aged 9 and older with moderate or severe non-nodular AV, who were treated with sarecycline for 12 weeks, demonstrating significant improvements in symptoms and psychosocial impacts as measured by the Acne Symptom and Impact Scale.
- Results showed a 58.9% success rate in reducing AV severity and 88.1% physician satisfaction, with some patients reporting side effects, highlighting the efficacy of oral antibiotic treatment in managing AV symptoms.
Article Synopsis
- A study was conducted over 12 weeks involving 253 patients aged 9 and older with moderate to severe facial acne vulgaris (AV) who were treated with sarecycline, assessing the impact of AV on daily life using a specialized questionnaire.
- Significant improvements were noted in emotional and social well-being, with many patients reporting reduced feelings of anger, worry, and social anxiety related to their acne.
- Despite positive patient-reported outcomes, caregivers did not show a notable improvement in understanding their child's AV-related concerns throughout the study.
Biography: Volker Koscielny, MD, is the Vice President, Global Medical Affairs, for Inflammation and Immunology at Celgene. Volker trained as a doctor in his native Germany and worked for several pharmaceutical companies prior to joining Celgene in January 2015.
View Article and Find Full Text PDFFirst Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study.
Rheumatol Ther
December 2016
Article Synopsis
- - The OBSErve Germany study was the first observational research analyzing belimumab as a supplementary treatment for systemic lupus erythematosus (SLE), involving data from 102 patients before and after starting the medication.
- - After 6 months of treatment, 78% of patients experienced at least a 20% improvement in disease activity, with 42% showing at least a 50% improvement, and notable reductions in SLE Disease Activity Index scores and oral corticosteroid dosage were observed.
- - Belimumab was found to be well-tolerated with a low discontinuation rate (only six patients), indicating promising real-world efficacy for managing SLE.
Background: The anti-TNF inhibitor, etanercept is administered as a once or twice weekly subcutaneous injection for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis (JIA). Limited data from the patients' perspective are available on the use of biologics in the treatment of these chronic conditions and this evaluation was designed to collect data from patients who had been prescribed etanercept for the first time. This manuscript describes the self-reported baseline characteristics and health-related quality of life of patients prior to treatment.
View Article and Find Full Text PDF